Josep Tabernero Caturla-rekin lankidetzan egindako argitalpenak (8)

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2012

  1. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  2. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  3. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

1995

  1. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 34, Núm. 1, pp. 15-24

1994

  1. Chop chemotherapy of intermediate and high-grade non-hodgkin's lymphoma

    Acta Oncologica, Vol. 33, Núm. 8, pp. 935-939

1993

  1. False elevations of alpha‐fetoprotein associated with liver dysfunction in germ cell tumors

    Cancer, Vol. 72, Núm. 8, pp. 2491-2494

  2. METASTASIS BILATERAL DE MAMA DE FIBROHISTIOCITOMA MALIGNO

    Oncologia, Vol. 16, Núm. 3, pp. 70-74